Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase 2 Study Neo-Adjuvant BRAF/MEK Inhibition Followed by Surgery and Adjuvant BRAF/MEK Inhibition in In-transit Melanoma Metastases (NASAM)

NCT05767879 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT05767879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05767879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase 2 Study Neo-Adjuvant BRAF/MEK Inhibition Followed by Surgery and Adjuvant BRAF/MEK Inhibition in In-transit Melanoma Metastases (NASAM)
Lead sponsor
Leiden University Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2022
Completion date
January 1, 2026
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

in-transit metastasis of cutaneous melanoma, melanoma stage iii